Cambridge Healthtech Institute’s 12th Annual
Circulating Tumor Cells and Liquid Biopsy
Enabling Precision Oncology for Diagnostic and Drug Development
FEBRUARY 21-22, 2022

Liquid biopsy is a maturing technology for early detection of disease, patient stratification and therapy selection, monitoring response to therapy, and detecting disease recurrence. Cambridge Healthtech Institute’s 12th Annual Circulating Tumor Cells and Liquid Biopsy meeting will explore the latest technologies in detection and molecular characterization of CTCs, cell-free circulating tumor DNA (cfDNA) and circulating extracellular RNA, exosomes and microvesicles, as well as the applications of liquid biopsy in diagnostics and drug development.